| Similar Articles |
|---|
 |
The Motley Fool
January 31, 2006
Stephen D. Simpson |
Poring Over Millipore The life sciences R&D industry has room to grow. This stock price may not.   |
The Motley Fool
February 14, 2006
Stephen D. Simpson |
Looking for a Hook at Fisher Scientific Growth and market share are great, but return on invested capital tells the tale in the end. Investors, think twice before putting your money with this one. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
The Motley Fool
May 2, 2006
Ryan Fuhrmann |
Sigma-Aldrich Surpasses Average Don't be fooled by appearances -- this isn't your typical chemical company. The shares have had a nice run over the past year, from about $55 to around $68.39. Even at current levels, the shares may be worth picking up, since they appear fairly valued. |
The Motley Fool
October 30, 2006
Ralph Casale |
Sigma-Aldrich Ekes Out Organic Growth Share buybacks and a dividend help offset some mixed news from this biotech/chemical company. Investors, take note. |
Chemistry World
April 20, 2009
Phil Taylor |
GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'. |
The Motley Fool
May 2, 2006
Stephen D. Simpson |
Still Fishing for Value at Fisher At the right price, this would be an interesting play on health care and biomedical research. Investors, take note. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
October 24, 2006
Brian Lawler |
Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
August 14, 2007
Brian Orelli |
Drugmaker Growth Without the FDA Do you have one of those stomachs that just can't take the ups and downs of clinical trial data and FDA approval decisions? Buy stocks in the companies that support the drug makers. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool
November 9, 2005
Stephen D. Simpson |
Fishing for Value at Fisher Even with today's earnings-induced jump, there still might be some value here at researcher Fisher Scientific. Investors, take note. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
Bio-IT World
October 14, 2004
Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
The Motley Fool
February 12, 2007
Brian Lawler |
I Love Drug Stocks This Valentine's Day, leave a special place in your heart for drug stocks. |
Chemistry World
September 26, 2014
Rebecca Trager |
Merck KGaA to buy Sigma--Aldrich German chemicals conglomerate Merck KGaA has agreed to buy US specialty chemicals company Sigma -- Aldrich for $17 billion |
The Motley Fool
April 19, 2006
Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge. |
Bio-IT World
December 10, 2002
Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. |
The Motley Fool
July 26, 2006
Ryan Fuhrmann |
Sigma-Aldrich's Steady Growth Growth at this life science company is steady, not spectacular. With a current stock price of $67.78, the shares trade at about 17 times projected earnings. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
The Motley Fool
August 18, 2010
Travers & Jayson |
The Most Important Thing About Human Genome Sciences Is Human Genome Sciences on strong financial footing? Take a look. |
Chemistry World
February 4, 2010
Matt Wilkinson |
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
The Motley Fool
October 26, 2007
Brian Orelli |
This Just In: Mergers Do Indeed Lower Costs As the anniversary integration between Thermo Electron and Fisher Scientific approaches next week, Thermo Fisher Scientific announced third-quarter results that demonstrated how the integration is having a nice effect on the bottom line. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
Pharmaceutical Executive
September 1, 2006
Bill Trombetta |
Industry Audit This fifth annual report dives deep into the numbers and comes up with the pharmaceutical industry's true top performers. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
Chemistry World
February 2008
Nuala Moran |
The Chemistry of Private Equity Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies? |
The Motley Fool
July 12, 2004
Ben McClure |
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good. |
The Motley Fool
February 7, 2008
Brian Orelli |
A Lab Match Made in Heaven The case of Thermo Electron and Fisher Scientific shows why mergers work. |
HBS Working Knowledge
November 13, 2006
Sean Silverthorne |
Science Business: What Happened to Biotech? The biotech industry has underperformed expectations, caught in the conflicting objectives and requirements between science and business. |
BusinessWeek
September 19, 2005 |
Biotech, Then and Now Amgen's George Rathmann explains how Big Pharma's role has evolved from detractor to investor, and why R&D needs more respect. |
Chemistry World
October 28, 2014
Phillip Broadwith |
Amgen stacks up additional job cuts US biotech heavyweight Amgen is to cut an extra 600 -- 1100 jobs by the end of 2015, on top of the 2900 the company earmarked for the chop in August. |
